Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Status:
Recruiting
Trial end date:
2029-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized, single-center, phase II study to evaluate the
efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens
in lung cancer patients with comorbidities.